TNF Antibody

ESBA-105 represents a highly stable, humanized single-chain Fv (scFv) antibody fragment specifically engineered to target and neutralize human tumor necrosis factor-alpha (TNF-α) with exceptional binding affinity. It effectively facilitates the measurable blockade of TNF-mediated pro-inflammatory signaling and apoptosis across various preclinical experimental models to evaluate the optimization of tissue penetration and pharmacokinetic stability during strictly monitored laboratory observation periods and functional neutralization assays.